nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—appendage—germ cell cancer	0.0211	0.0932	CbGeAlD
Everolimus—MTOR—blood vessel—germ cell cancer	0.0117	0.0519	CbGeAlD
Everolimus—MTOR—neck—germ cell cancer	0.00839	0.0371	CbGeAlD
Everolimus—FKBP1A—neck—germ cell cancer	0.00755	0.0334	CbGeAlD
Everolimus—MTOR—embryo—germ cell cancer	0.007	0.0309	CbGeAlD
Everolimus—FKBP1A—trigeminal ganglion—germ cell cancer	0.00652	0.0288	CbGeAlD
Everolimus—MTOR—brainstem—germ cell cancer	0.00641	0.0284	CbGeAlD
Everolimus—CYP3A4—urine—germ cell cancer	0.00636	0.0281	CbGeAlD
Everolimus—MTOR—eye—germ cell cancer	0.00624	0.0276	CbGeAlD
Everolimus—MTOR—retina—germ cell cancer	0.00619	0.0274	CbGeAlD
Everolimus—MTOR—telencephalon—germ cell cancer	0.00569	0.0252	CbGeAlD
Everolimus—FKBP1A—eye—germ cell cancer	0.00561	0.0248	CbGeAlD
Everolimus—FKBP1A—retina—germ cell cancer	0.00556	0.0246	CbGeAlD
Everolimus—MTOR—skin of body—germ cell cancer	0.00543	0.024	CbGeAlD
Everolimus—FKBP1A—telencephalon—germ cell cancer	0.00512	0.0226	CbGeAlD
Everolimus—FKBP1A—skin of body—germ cell cancer	0.00488	0.0216	CbGeAlD
Everolimus—FKBP1A—decidua—germ cell cancer	0.00485	0.0215	CbGeAlD
Everolimus—MTOR—gonad—germ cell cancer	0.00475	0.021	CbGeAlD
Everolimus—MTOR—uterus—germ cell cancer	0.00472	0.0209	CbGeAlD
Everolimus—MTOR—pituitary gland—germ cell cancer	0.00463	0.0205	CbGeAlD
Everolimus—FKBP1A—gonad—germ cell cancer	0.00427	0.0189	CbGeAlD
Everolimus—FKBP1A—uterus—germ cell cancer	0.00424	0.0188	CbGeAlD
Everolimus—FKBP1A—pituitary gland—germ cell cancer	0.00417	0.0184	CbGeAlD
Everolimus—MTOR—adrenal gland—germ cell cancer	0.00414	0.0183	CbGeAlD
Everolimus—FKBP1A—medulla oblongata—germ cell cancer	0.00402	0.0178	CbGeAlD
Everolimus—MTOR—bone marrow—germ cell cancer	0.004	0.0177	CbGeAlD
Everolimus—MTOR—spinal cord—germ cell cancer	0.00399	0.0176	CbGeAlD
Everolimus—MTOR—female gonad—germ cell cancer	0.00386	0.0171	CbGeAlD
Everolimus—FKBP1A—adrenal gland—germ cell cancer	0.00372	0.0165	CbGeAlD
Everolimus—FKBP1A—midbrain—germ cell cancer	0.00368	0.0163	CbGeAlD
Everolimus—FKBP1A—bone marrow—germ cell cancer	0.0036	0.0159	CbGeAlD
Everolimus—MTOR—endocrine gland—germ cell cancer	0.00359	0.0159	CbGeAlD
Everolimus—FKBP1A—spinal cord—germ cell cancer	0.00359	0.0159	CbGeAlD
Everolimus—MTOR—head—germ cell cancer	0.00354	0.0157	CbGeAlD
Everolimus—FKBP1A—female gonad—germ cell cancer	0.00347	0.0154	CbGeAlD
Everolimus—MTOR—testis—germ cell cancer	0.00342	0.0151	CbGeAlD
Everolimus—FKBP1A—endocrine gland—germ cell cancer	0.00323	0.0143	CbGeAlD
Everolimus—FKBP1A—head—germ cell cancer	0.00319	0.0141	CbGeAlD
Everolimus—MTOR—cerebellum—germ cell cancer	0.00316	0.014	CbGeAlD
Everolimus—FKBP1A—testis—germ cell cancer	0.00308	0.0136	CbGeAlD
Everolimus—FKBP1A—cerebellum—germ cell cancer	0.00284	0.0126	CbGeAlD
Everolimus—MTOR—Cellular responses to stress—PHC1—germ cell cancer	0.00265	0.0206	CbGpPWpGaD
Everolimus—MTOR—brain—germ cell cancer	0.00257	0.0114	CbGeAlD
Everolimus—MTOR—lymph node—germ cell cancer	0.00248	0.011	CbGeAlD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—HRAS—germ cell cancer	0.00232	0.018	CbGpPWpGaD
Everolimus—FKBP1A—brain—germ cell cancer	0.00231	0.0102	CbGeAlD
Everolimus—FKBP1A—lymph node—germ cell cancer	0.00223	0.00987	CbGeAlD
Everolimus—MTOR—PI3K Cascade—FGF4—germ cell cancer	0.0019	0.0147	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—FGF4—germ cell cancer	0.00159	0.0123	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGF4—germ cell cancer	0.00157	0.0122	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—FGF4—germ cell cancer	0.00154	0.012	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—FGF4—germ cell cancer	0.00153	0.0119	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—NAT9—germ cell cancer	0.00151	0.0118	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—FGF4—germ cell cancer	0.00149	0.0116	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—FGF4—germ cell cancer	0.00149	0.0116	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FGF4—germ cell cancer	0.00142	0.011	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGF4—germ cell cancer	0.00138	0.0107	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—ALPL—germ cell cancer	0.00137	0.0107	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGF4—germ cell cancer	0.00137	0.0107	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGF4—germ cell cancer	0.00134	0.0104	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—germ cell cancer	0.00129	0.01	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGF4—germ cell cancer	0.00124	0.00962	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—KITLG—germ cell cancer	0.00116	0.00904	CbGpPWpGaD
Everolimus—MTOR—PI3K Cascade—FGFR3—germ cell cancer	0.00116	0.009	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—KITLG—germ cell cancer	0.00114	0.00882	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—KITLG—germ cell cancer	0.00113	0.00876	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—germ cell cancer	0.0011	0.00855	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGF4—germ cell cancer	0.00106	0.00823	CbGpPWpGaD
Everolimus—CYP3A4—endocrine gland—germ cell cancer	0.00106	0.00467	CbGeAlD
Everolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—MYC—germ cell cancer	0.00102	0.0079	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGF4—germ cell cancer	0.00101	0.00787	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGF4—germ cell cancer	0.000996	0.00775	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—HRAS—germ cell cancer	0.000982	0.00764	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—FGFR3—germ cell cancer	0.000968	0.00753	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—germ cell cancer	0.000959	0.00746	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—MYC—germ cell cancer	0.000952	0.0074	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGF4—germ cell cancer	0.000951	0.0074	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGF4—germ cell cancer	0.000947	0.00736	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGF4—germ cell cancer	0.000942	0.00732	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—FGFR3—germ cell cancer	0.000942	0.00732	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGF4—germ cell cancer	0.000937	0.00729	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—germ cell cancer	0.000933	0.00726	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF4—germ cell cancer	0.000924	0.00718	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—FGFR3—germ cell cancer	0.000909	0.00707	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—FGFR3—germ cell cancer	0.000909	0.00707	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—HRAS—germ cell cancer	0.000884	0.00687	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF4—germ cell cancer	0.000882	0.00686	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGF4—germ cell cancer	0.000882	0.00686	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGF4—germ cell cancer	0.000882	0.00686	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—germ cell cancer	0.000881	0.00685	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGF4—germ cell cancer	0.000874	0.0068	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KITLG—germ cell cancer	0.000869	0.00676	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGF4—germ cell cancer	0.000866	0.00674	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FGFR3—germ cell cancer	0.000864	0.00672	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGF4—germ cell cancer	0.000863	0.00671	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—MYC—germ cell cancer	0.000844	0.00656	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGFR3—germ cell cancer	0.000844	0.00656	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGFR3—germ cell cancer	0.000837	0.00651	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KITLG—germ cell cancer	0.000832	0.00647	CbGpPWpGaD
Everolimus—MTOR—Alpha 6 Beta 4 signaling pathway—HRAS—germ cell cancer	0.000819	0.00637	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KITLG—germ cell cancer	0.000818	0.00636	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—germ cell cancer	0.000818	0.00636	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGF4—germ cell cancer	0.000816	0.00635	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—KIT—germ cell cancer	0.000793	0.00617	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—MYC—germ cell cancer	0.000786	0.00611	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KITLG—germ cell cancer	0.000782	0.00608	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF4—germ cell cancer	0.000781	0.00607	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KITLG—germ cell cancer	0.000778	0.00605	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—KIT—germ cell cancer	0.000775	0.00602	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KITLG—germ cell cancer	0.000774	0.00602	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KITLG—germ cell cancer	0.00077	0.00599	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—KIT—germ cell cancer	0.000768	0.00597	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—germ cell cancer	0.000759	0.0059	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGFR3—germ cell cancer	0.000755	0.00587	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—germ cell cancer	0.000751	0.00584	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—HRAS—germ cell cancer	0.000732	0.00569	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—MYC—germ cell cancer	0.000725	0.00564	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KITLG—germ cell cancer	0.000725	0.00563	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KITLG—germ cell cancer	0.000725	0.00563	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KITLG—germ cell cancer	0.000725	0.00563	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KITLG—germ cell cancer	0.000718	0.00558	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KITLG—germ cell cancer	0.000712	0.00553	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KITLG—germ cell cancer	0.000709	0.00551	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—MYC—germ cell cancer	0.000703	0.00547	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—germ cell cancer	0.000693	0.00539	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—germ cell cancer	0.000688	0.00535	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KITLG—germ cell cancer	0.000671	0.00521	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MYC—germ cell cancer	0.000669	0.0052	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGFR3—germ cell cancer	0.000646	0.00502	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KITLG—germ cell cancer	0.000642	0.00499	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—germ cell cancer	0.000618	0.00481	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGFR3—germ cell cancer	0.000608	0.00473	CbGpPWpGaD
Everolimus—Palpitations—Ifosfamide—germ cell cancer	0.000601	0.000932	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—FGF4—germ cell cancer	0.000601	0.00467	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—MYC—germ cell cancer	0.000599	0.00466	CbGpPWpGaD
Everolimus—Alopecia—Cisplatin—germ cell cancer	0.000595	0.000923	CcSEcCtD
Everolimus—Hepatic failure—Methotrexate—germ cell cancer	0.000595	0.000922	CcSEcCtD
Everolimus—Cough—Ifosfamide—germ cell cancer	0.000594	0.00092	CcSEcCtD
Everolimus—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000593	0.00092	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—KIT—germ cell cancer	0.000593	0.00461	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000592	0.000917	CcSEcCtD
Everolimus—Convulsion—Ifosfamide—germ cell cancer	0.00059	0.000914	CcSEcCtD
Everolimus—Hypertension—Ifosfamide—germ cell cancer	0.000587	0.00091	CcSEcCtD
Everolimus—Erythema—Cisplatin—germ cell cancer	0.000587	0.000909	CcSEcCtD
Everolimus—Malnutrition—Cisplatin—germ cell cancer	0.000587	0.000909	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—MYC—germ cell cancer	0.000585	0.00455	CbGpPWpGaD
Everolimus—Paraesthesia—Bleomycin—germ cell cancer	0.000583	0.000904	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—FGFR3—germ cell cancer	0.000581	0.00452	CbGpPWpGaD
Everolimus—Dyspnoea—Bleomycin—germ cell cancer	0.000579	0.000898	CcSEcCtD
Everolimus—Myalgia—Ifosfamide—germ cell cancer	0.000579	0.000898	CcSEcCtD
Everolimus—Arthralgia—Ifosfamide—germ cell cancer	0.000579	0.000898	CcSEcCtD
Everolimus—Chest pain—Ifosfamide—germ cell cancer	0.000579	0.000898	CcSEcCtD
Everolimus—Renal failure acute—Methotrexate—germ cell cancer	0.000579	0.000897	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—FGFR3—germ cell cancer	0.000578	0.00449	CbGpPWpGaD
Everolimus—Flatulence—Cisplatin—germ cell cancer	0.000578	0.000896	CcSEcCtD
Everolimus—Anorexia—Dactinomycin—germ cell cancer	0.000578	0.000895	CcSEcCtD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—germ cell cancer	0.000578	0.00449	CbGpPWpGaD
Everolimus—Eye disorder—Etoposide—germ cell cancer	0.000577	0.000894	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000575	0.000892	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—FGFR3—germ cell cancer	0.000575	0.00447	CbGpPWpGaD
Everolimus—Cardiac disorder—Etoposide—germ cell cancer	0.000573	0.000888	CcSEcCtD
Everolimus—Flushing—Etoposide—germ cell cancer	0.000573	0.000888	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—FGFR3—germ cell cancer	0.000572	0.00445	CbGpPWpGaD
Everolimus—Discomfort—Ifosfamide—germ cell cancer	0.000572	0.000887	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—H2AFZ—germ cell cancer	0.000572	0.00445	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC2A3—germ cell cancer	0.00057	0.00444	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KIT—germ cell cancer	0.000567	0.00441	CbGpPWpGaD
Everolimus—Hypersensitivity—Vinblastine—germ cell cancer	0.000567	0.000878	CcSEcCtD
Everolimus—Dermatitis exfoliative—Methotrexate—germ cell cancer	0.000566	0.000878	CcSEcCtD
Everolimus—Decreased appetite—Bleomycin—germ cell cancer	0.000565	0.000875	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—germ cell cancer	0.000564	0.00439	CbGpPWpGaD
Everolimus—Muscle spasms—Cisplatin—germ cell cancer	0.000564	0.000874	CcSEcCtD
Everolimus—Angiopathy—Etoposide—germ cell cancer	0.00056	0.000868	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—KIT—germ cell cancer	0.000558	0.00434	CbGpPWpGaD
Everolimus—Immune system disorder—Etoposide—germ cell cancer	0.000558	0.000864	CcSEcCtD
Everolimus—Mediastinal disorder—Etoposide—germ cell cancer	0.000556	0.000862	CcSEcCtD
Everolimus—Pain—Bleomycin—germ cell cancer	0.000556	0.000861	CcSEcCtD
Everolimus—Oedema—Ifosfamide—germ cell cancer	0.000555	0.000861	CcSEcCtD
Everolimus—Chills—Etoposide—germ cell cancer	0.000554	0.000858	CcSEcCtD
Everolimus—Vision blurred—Cisplatin—germ cell cancer	0.000553	0.000857	CcSEcCtD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—germ cell cancer	0.000552	0.00429	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000552	0.000856	CcSEcCtD
Everolimus—Asthenia—Vinblastine—germ cell cancer	0.000552	0.000855	CcSEcCtD
Everolimus—Infection—Ifosfamide—germ cell cancer	0.000552	0.000855	CcSEcCtD
Everolimus—Tremor—Cisplatin—germ cell cancer	0.00055	0.000852	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—germ cell cancer	0.000549	0.00427	CbGpPWpGaD
Everolimus—Alopecia—Etoposide—germ cell cancer	0.000545	0.000845	CcSEcCtD
Everolimus—Lethargy—Methotrexate—germ cell cancer	0.000545	0.000845	CcSEcCtD
Everolimus—Nervous system disorder—Ifosfamide—germ cell cancer	0.000545	0.000844	CcSEcCtD
Everolimus—Ill-defined disorder—Cisplatin—germ cell cancer	0.000544	0.000844	CcSEcCtD
Everolimus—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000544	0.000843	CcSEcCtD
Everolimus—Anaemia—Cisplatin—germ cell cancer	0.000542	0.00084	CcSEcCtD
Everolimus—Skin disorder—Ifosfamide—germ cell cancer	0.000539	0.000836	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—FGFR3—germ cell cancer	0.000539	0.00419	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGFR3—germ cell cancer	0.000539	0.00419	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	0.000539	0.00419	CbGpPWpGaD
Everolimus—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000537	0.000832	CcSEcCtD
Everolimus—Feeling abnormal—Bleomycin—germ cell cancer	0.000535	0.00083	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—FGFR3—germ cell cancer	0.000534	0.00415	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KIT—germ cell cancer	0.000533	0.00415	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KIT—germ cell cancer	0.000531	0.00413	CbGpPWpGaD
Everolimus—Anorexia—Ifosfamide—germ cell cancer	0.000529	0.00082	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	0.000529	0.00411	CbGpPWpGaD
Everolimus—Malaise—Cisplatin—germ cell cancer	0.000529	0.00082	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—KIT—germ cell cancer	0.000528	0.00411	CbGpPWpGaD
Everolimus—Decreased appetite—Dactinomycin—germ cell cancer	0.000527	0.000816	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—FGFR3—germ cell cancer	0.000527	0.00409	CbGpPWpGaD
Everolimus—Diarrhoea—Vinblastine—germ cell cancer	0.000526	0.000816	CcSEcCtD
Everolimus—Dysgeusia—Etoposide—germ cell cancer	0.000526	0.000816	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—KIT—germ cell cancer	0.000526	0.00409	CbGpPWpGaD
Everolimus—Leukopenia—Cisplatin—germ cell cancer	0.000525	0.000814	CcSEcCtD
Everolimus—Fatigue—Dactinomycin—germ cell cancer	0.000522	0.00081	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PVRL2—germ cell cancer	0.000521	0.00405	CbGpPWpGaD
Everolimus—Back pain—Etoposide—germ cell cancer	0.00052	0.000806	CcSEcCtD
Everolimus—Hypotension—Ifosfamide—germ cell cancer	0.000519	0.000804	CcSEcCtD
Everolimus—Pain—Dactinomycin—germ cell cancer	0.000518	0.000803	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—germ cell cancer	0.000518	0.00403	CbGpPWpGaD
Everolimus—Muscle spasms—Etoposide—germ cell cancer	0.000517	0.000801	CcSEcCtD
Everolimus—Body temperature increased—Bleomycin—germ cell cancer	0.000514	0.000796	CcSEcCtD
Everolimus—Irritability—Methotrexate—germ cell cancer	0.00051	0.000791	CcSEcCtD
Everolimus—Dizziness—Vinblastine—germ cell cancer	0.000509	0.000788	CcSEcCtD
Everolimus—Convulsion—Cisplatin—germ cell cancer	0.000508	0.000788	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000506	0.000784	CcSEcCtD
Everolimus—Myalgia—Cisplatin—germ cell cancer	0.000499	0.000774	CcSEcCtD
Everolimus—Feeling abnormal—Dactinomycin—germ cell cancer	0.000499	0.000774	CcSEcCtD
Everolimus—Paraesthesia—Ifosfamide—germ cell cancer	0.000499	0.000773	CcSEcCtD
Everolimus—Ill-defined disorder—Etoposide—germ cell cancer	0.000499	0.000773	CcSEcCtD
Everolimus—MTOR—B Cell Activation—FGFR3—germ cell cancer	0.000498	0.00387	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—germ cell cancer	0.000498	0.00387	CbGpPWpGaD
Everolimus—Anxiety—Cisplatin—germ cell cancer	0.000498	0.000771	CcSEcCtD
Everolimus—Anaemia—Etoposide—germ cell cancer	0.000497	0.00077	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000496	0.000769	CcSEcCtD
Everolimus—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000496	0.000768	CcSEcCtD
Everolimus—Dyspnoea—Ifosfamide—germ cell cancer	0.000495	0.000767	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—KIT—germ cell cancer	0.000494	0.00384	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KIT—germ cell cancer	0.000494	0.00384	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	0.000494	0.00384	CbGpPWpGaD
Everolimus—Somnolence—Ifosfamide—germ cell cancer	0.000494	0.000765	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KITLG—germ cell cancer	0.000494	0.00384	CbGpPWpGaD
Everolimus—Liver function test abnormal—Methotrexate—germ cell cancer	0.000493	0.000765	CcSEcCtD
Everolimus—Discomfort—Cisplatin—germ cell cancer	0.000493	0.000765	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—KIT—germ cell cancer	0.00049	0.00381	CbGpPWpGaD
Everolimus—Vomiting—Vinblastine—germ cell cancer	0.000489	0.000758	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—KIT—germ cell cancer	0.000486	0.00378	CbGpPWpGaD
Everolimus—Malaise—Etoposide—germ cell cancer	0.000485	0.000751	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—KIT—germ cell cancer	0.000484	0.00376	CbGpPWpGaD
Everolimus—Breast disorder—Methotrexate—germ cell cancer	0.000483	0.000749	CcSEcCtD
Everolimus—Decreased appetite—Ifosfamide—germ cell cancer	0.000483	0.000748	CcSEcCtD
Everolimus—Headache—Vinblastine—germ cell cancer	0.000482	0.000747	CcSEcCtD
Everolimus—Leukopenia—Etoposide—germ cell cancer	0.000481	0.000746	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000479	0.000743	CcSEcCtD
Everolimus—Abdominal pain—Dactinomycin—germ cell cancer	0.000479	0.000742	CcSEcCtD
Everolimus—Body temperature increased—Dactinomycin—germ cell cancer	0.000479	0.000742	CcSEcCtD
Everolimus—Fatigue—Ifosfamide—germ cell cancer	0.000479	0.000742	CcSEcCtD
Everolimus—Oedema—Cisplatin—germ cell cancer	0.000479	0.000742	CcSEcCtD
Everolimus—Hypersensitivity—Bleomycin—germ cell cancer	0.000479	0.000742	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	0.000477	0.00371	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—germ cell cancer	0.000476	0.0037	CbGpPWpGaD
Everolimus—Infection—Cisplatin—germ cell cancer	0.000476	0.000737	CcSEcCtD
Everolimus—Constipation—Ifosfamide—germ cell cancer	0.000475	0.000736	CcSEcCtD
Everolimus—Pain—Ifosfamide—germ cell cancer	0.000475	0.000736	CcSEcCtD
Everolimus—MTOR—AMPK Signaling—TP53—germ cell cancer	0.000475	0.00369	CbGpPWpGaD
Everolimus—Loss of consciousness—Etoposide—germ cell cancer	0.000472	0.000732	CcSEcCtD
Everolimus—MTOR—mTOR signaling pathway—HRAS—germ cell cancer	0.00047	0.00366	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—HRAS—germ cell cancer	0.00047	0.00366	CbGpPWpGaD
Everolimus—Nervous system disorder—Cisplatin—germ cell cancer	0.000469	0.000728	CcSEcCtD
Everolimus—Cough—Etoposide—germ cell cancer	0.000469	0.000727	CcSEcCtD
Everolimus—Thrombocytopenia—Cisplatin—germ cell cancer	0.000469	0.000726	CcSEcCtD
Everolimus—Tachycardia—Cisplatin—germ cell cancer	0.000467	0.000724	CcSEcCtD
Everolimus—Asthenia—Bleomycin—germ cell cancer	0.000466	0.000722	CcSEcCtD
Everolimus—Convulsion—Etoposide—germ cell cancer	0.000466	0.000722	CcSEcCtD
Everolimus—Skin disorder—Cisplatin—germ cell cancer	0.000465	0.000721	CcSEcCtD
Everolimus—Hypertension—Etoposide—germ cell cancer	0.000464	0.000719	CcSEcCtD
Everolimus—Hyperhidrosis—Cisplatin—germ cell cancer	0.000463	0.000717	CcSEcCtD
Everolimus—Pruritus—Bleomycin—germ cell cancer	0.00046	0.000712	CcSEcCtD
Everolimus—Feeling abnormal—Ifosfamide—germ cell cancer	0.000458	0.000709	CcSEcCtD
Everolimus—MTOR—B Cell Activation—KIT—germ cell cancer	0.000458	0.00356	CbGpPWpGaD
Everolimus—Chest pain—Etoposide—germ cell cancer	0.000458	0.000709	CcSEcCtD
Everolimus—Nausea—Vinblastine—germ cell cancer	0.000457	0.000708	CcSEcCtD
Everolimus—Anorexia—Cisplatin—germ cell cancer	0.000456	0.000707	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	0.000455	0.00354	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000454	0.000704	CcSEcCtD
Everolimus—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.000454	0.000704	CcSEcCtD
Everolimus—Pancreatitis—Methotrexate—germ cell cancer	0.000453	0.000702	CcSEcCtD
Everolimus—Discomfort—Etoposide—germ cell cancer	0.000452	0.000701	CcSEcCtD
Everolimus—MTOR—CDC42 signaling events—HRAS—germ cell cancer	0.000449	0.00349	CbGpPWpGaD
Everolimus—Hypotension—Cisplatin—germ cell cancer	0.000447	0.000693	CcSEcCtD
Everolimus—Hypersensitivity—Dactinomycin—germ cell cancer	0.000446	0.000692	CcSEcCtD
Everolimus—Body temperature increased—Ifosfamide—germ cell cancer	0.000439	0.00068	CcSEcCtD
Everolimus—Abdominal pain—Ifosfamide—germ cell cancer	0.000439	0.00068	CcSEcCtD
Everolimus—Pancytopenia—Methotrexate—germ cell cancer	0.000439	0.00068	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000438	0.0034	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000436	0.000676	CcSEcCtD
Everolimus—Infection—Etoposide—germ cell cancer	0.000436	0.000675	CcSEcCtD
Everolimus—Asthenia—Dactinomycin—germ cell cancer	0.000435	0.000674	CcSEcCtD
Everolimus—Neutropenia—Methotrexate—germ cell cancer	0.000432	0.000669	CcSEcCtD
Everolimus—Dysuria—Methotrexate—germ cell cancer	0.000432	0.000669	CcSEcCtD
Everolimus—Paraesthesia—Cisplatin—germ cell cancer	0.00043	0.000666	CcSEcCtD
Everolimus—Thrombocytopenia—Etoposide—germ cell cancer	0.000429	0.000666	CcSEcCtD
Everolimus—Upper respiratory tract infection—Methotrexate—germ cell cancer	0.000429	0.000665	CcSEcCtD
Everolimus—Tachycardia—Etoposide—germ cell cancer	0.000428	0.000663	CcSEcCtD
Everolimus—Dyspnoea—Cisplatin—germ cell cancer	0.000427	0.000661	CcSEcCtD
Everolimus—Skin disorder—Etoposide—germ cell cancer	0.000426	0.00066	CcSEcCtD
Everolimus—Erectile dysfunction—Methotrexate—germ cell cancer	0.000425	0.000659	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—HRAS—germ cell cancer	0.000425	0.0033	CbGpPWpGaD
Everolimus—Hyperhidrosis—Etoposide—germ cell cancer	0.000424	0.000657	CcSEcCtD
Everolimus—Anorexia—Etoposide—germ cell cancer	0.000418	0.000648	CcSEcCtD
Everolimus—Decreased appetite—Cisplatin—germ cell cancer	0.000416	0.000645	CcSEcCtD
Everolimus—Diarrhoea—Dactinomycin—germ cell cancer	0.000415	0.000643	CcSEcCtD
Everolimus—Pneumonia—Methotrexate—germ cell cancer	0.000414	0.000642	CcSEcCtD
Everolimus—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000413	0.000641	CcSEcCtD
Everolimus—Vomiting—Bleomycin—germ cell cancer	0.000413	0.00064	CcSEcCtD
Everolimus—Infestation NOS—Methotrexate—germ cell cancer	0.000412	0.000638	CcSEcCtD
Everolimus—Infestation—Methotrexate—germ cell cancer	0.000412	0.000638	CcSEcCtD
Everolimus—Hypotension—Etoposide—germ cell cancer	0.00041	0.000635	CcSEcCtD
Everolimus—Rash—Bleomycin—germ cell cancer	0.00041	0.000635	CcSEcCtD
Everolimus—Pain—Cisplatin—germ cell cancer	0.000409	0.000634	CcSEcCtD
Everolimus—Dermatitis—Bleomycin—germ cell cancer	0.000409	0.000634	CcSEcCtD
Everolimus—Hypersensitivity—Ifosfamide—germ cell cancer	0.000409	0.000634	CcSEcCtD
Everolimus—Renal failure—Methotrexate—germ cell cancer	0.000405	0.000628	CcSEcCtD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—germ cell cancer	0.000403	0.00314	CbGpPWpGaD
Everolimus—Stomatitis—Methotrexate—germ cell cancer	0.000401	0.000622	CcSEcCtD
Everolimus—Conjunctivitis—Methotrexate—germ cell cancer	0.0004	0.000621	CcSEcCtD
Everolimus—Asthenia—Ifosfamide—germ cell cancer	0.000398	0.000617	CcSEcCtD
Everolimus—Feeling abnormal—Cisplatin—germ cell cancer	0.000394	0.000611	CcSEcCtD
Everolimus—Paraesthesia—Etoposide—germ cell cancer	0.000394	0.00061	CcSEcCtD
Everolimus—Pruritus—Ifosfamide—germ cell cancer	0.000393	0.000609	CcSEcCtD
Everolimus—Haematuria—Methotrexate—germ cell cancer	0.000393	0.000609	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—germ cell cancer	0.000391	0.000606	CcSEcCtD
Everolimus—Somnolence—Etoposide—germ cell cancer	0.00039	0.000604	CcSEcCtD
Everolimus—Hepatobiliary disease—Methotrexate—germ cell cancer	0.00039	0.000604	CcSEcCtD
Everolimus—Epistaxis—Methotrexate—germ cell cancer	0.000389	0.000602	CcSEcCtD
Everolimus—Nausea—Bleomycin—germ cell cancer	0.000386	0.000598	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—germ cell cancer	0.000385	0.000597	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—HRAS—germ cell cancer	0.000384	0.00299	CbGpPWpGaD
Everolimus—Rash—Dactinomycin—germ cell cancer	0.000382	0.000592	CcSEcCtD
Everolimus—Decreased appetite—Etoposide—germ cell cancer	0.000381	0.000591	CcSEcCtD
Everolimus—Diarrhoea—Ifosfamide—germ cell cancer	0.00038	0.000589	CcSEcCtD
Everolimus—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000379	0.000587	CcSEcCtD
Everolimus—Body temperature increased—Cisplatin—germ cell cancer	0.000378	0.000587	CcSEcCtD
Everolimus—Fatigue—Etoposide—germ cell cancer	0.000378	0.000586	CcSEcCtD
Everolimus—Pain—Etoposide—germ cell cancer	0.000375	0.000581	CcSEcCtD
Everolimus—Constipation—Etoposide—germ cell cancer	0.000375	0.000581	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	0.000374	0.00291	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—germ cell cancer	0.000374	0.00291	CbGpPWpGaD
Everolimus—Haemoglobin—Methotrexate—germ cell cancer	0.000372	0.000576	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	0.00037	0.00288	CbGpPWpGaD
Everolimus—Haemorrhage—Methotrexate—germ cell cancer	0.00037	0.000573	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—germ cell cancer	0.00037	0.000573	CcSEcCtD
Everolimus—Dizziness—Ifosfamide—germ cell cancer	0.000367	0.000569	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—germ cell cancer	0.000367	0.000569	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—FGFR3—germ cell cancer	0.000367	0.00285	CbGpPWpGaD
Everolimus—Urinary tract disorder—Methotrexate—germ cell cancer	0.000365	0.000566	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—germ cell cancer	0.000362	0.000562	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—germ cell cancer	0.000361	0.00056	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—germ cell cancer	0.000361	0.0028	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—germ cell cancer	0.000361	0.0028	CbGpPWpGaD
Everolimus—Nausea—Dactinomycin—germ cell cancer	0.00036	0.000558	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—germ cell cancer	0.000359	0.000556	CcSEcCtD
Everolimus—Vomiting—Ifosfamide—germ cell cancer	0.000353	0.000547	CcSEcCtD
Everolimus—Hypersensitivity—Cisplatin—germ cell cancer	0.000353	0.000547	CcSEcCtD
Everolimus—Rash—Ifosfamide—germ cell cancer	0.00035	0.000543	CcSEcCtD
Everolimus—Dermatitis—Ifosfamide—germ cell cancer	0.00035	0.000542	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—germ cell cancer	0.000347	0.000537	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—germ cell cancer	0.000347	0.000537	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—germ cell cancer	0.000346	0.000536	CcSEcCtD
Everolimus—Asthenia—Cisplatin—germ cell cancer	0.000343	0.000532	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—germ cell cancer	0.000343	0.000532	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FGF4—germ cell cancer	0.000343	0.00266	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—germ cell cancer	0.000339	0.00264	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KIT—germ cell cancer	0.000337	0.00262	CbGpPWpGaD
Everolimus—Angiopathy—Methotrexate—germ cell cancer	0.000335	0.00052	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—germ cell cancer	0.000334	0.000518	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—germ cell cancer	0.000333	0.000516	CcSEcCtD
Everolimus—Chills—Methotrexate—germ cell cancer	0.000332	0.000514	CcSEcCtD
Everolimus—Nausea—Ifosfamide—germ cell cancer	0.00033	0.000511	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FGF4—germ cell cancer	0.000329	0.00256	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF4—germ cell cancer	0.000328	0.00255	CbGpPWpGaD
Everolimus—Diarrhoea—Cisplatin—germ cell cancer	0.000328	0.000508	CcSEcCtD
Everolimus—Alopecia—Methotrexate—germ cell cancer	0.000327	0.000506	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—germ cell cancer	0.000324	0.00252	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	0.000324	0.00252	CbGpPWpGaD
Everolimus—Mental disorder—Methotrexate—germ cell cancer	0.000324	0.000502	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—germ cell cancer	0.000323	0.000501	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—germ cell cancer	0.000322	0.000499	CcSEcCtD
Everolimus—Erythema—Methotrexate—germ cell cancer	0.000322	0.000499	CcSEcCtD
Everolimus—MTOR—Disease—SLC2A3—germ cell cancer	0.000321	0.00249	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—germ cell cancer	0.00032	0.00248	CbGpPWpGaD
Everolimus—MTOR—Immune System—PVRL2—germ cell cancer	0.000316	0.00246	CbGpPWpGaD
Everolimus—Dysgeusia—Methotrexate—germ cell cancer	0.000315	0.000489	CcSEcCtD
Everolimus—Asthenia—Etoposide—germ cell cancer	0.000315	0.000488	CcSEcCtD
Everolimus—Back pain—Methotrexate—germ cell cancer	0.000311	0.000483	CcSEcCtD
Everolimus—Pruritus—Etoposide—germ cell cancer	0.00031	0.000481	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—germ cell cancer	0.000309	0.0024	CbGpPWpGaD
Everolimus—Vomiting—Cisplatin—germ cell cancer	0.000304	0.000472	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—germ cell cancer	0.000303	0.00047	CcSEcCtD
Everolimus—Rash—Cisplatin—germ cell cancer	0.000302	0.000468	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—HRAS—germ cell cancer	0.000302	0.00235	CbGpPWpGaD
Everolimus—Dermatitis—Cisplatin—germ cell cancer	0.000302	0.000467	CcSEcCtD
Everolimus—Diarrhoea—Etoposide—germ cell cancer	0.0003	0.000465	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—germ cell cancer	0.0003	0.00233	CbGpPWpGaD
Everolimus—Ill-defined disorder—Methotrexate—germ cell cancer	0.000299	0.000463	CcSEcCtD
Everolimus—Anaemia—Methotrexate—germ cell cancer	0.000298	0.000461	CcSEcCtD
Everolimus—FKBP1A—Disease—H2AFZ—germ cell cancer	0.000293	0.00227	CbGpPWpGaD
Everolimus—Malaise—Methotrexate—germ cell cancer	0.00029	0.00045	CcSEcCtD
Everolimus—Dizziness—Etoposide—germ cell cancer	0.00029	0.000449	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—germ cell cancer	0.000288	0.000447	CcSEcCtD
Everolimus—Nausea—Cisplatin—germ cell cancer	0.000284	0.000441	CcSEcCtD
Everolimus—MTOR—Innate Immune System—KITLG—germ cell cancer	0.000282	0.00219	CbGpPWpGaD
Everolimus—Cough—Methotrexate—germ cell cancer	0.000281	0.000435	CcSEcCtD
Everolimus—Convulsion—Methotrexate—germ cell cancer	0.000279	0.000432	CcSEcCtD
Everolimus—Vomiting—Etoposide—germ cell cancer	0.000279	0.000432	CcSEcCtD
Everolimus—Rash—Etoposide—germ cell cancer	0.000277	0.000429	CcSEcCtD
Everolimus—Dermatitis—Etoposide—germ cell cancer	0.000276	0.000428	CcSEcCtD
Everolimus—Headache—Etoposide—germ cell cancer	0.000275	0.000426	CcSEcCtD
Everolimus—Chest pain—Methotrexate—germ cell cancer	0.000274	0.000425	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—germ cell cancer	0.000274	0.000425	CcSEcCtD
Everolimus—Myalgia—Methotrexate—germ cell cancer	0.000274	0.000425	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.000272	0.000422	CcSEcCtD
Everolimus—Discomfort—Methotrexate—germ cell cancer	0.000271	0.00042	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KITLG—germ cell cancer	0.00027	0.0021	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KITLG—germ cell cancer	0.000269	0.00209	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—OXT—germ cell cancer	0.000269	0.00209	CbGpPWpGaD
Everolimus—Infection—Methotrexate—germ cell cancer	0.000261	0.000404	CcSEcCtD
Everolimus—Nausea—Etoposide—germ cell cancer	0.000261	0.000404	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—germ cell cancer	0.000258	0.000399	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—germ cell cancer	0.000257	0.000399	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—germ cell cancer	0.000256	0.00199	CbGpPWpGaD
Everolimus—Skin disorder—Methotrexate—germ cell cancer	0.000255	0.000395	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—germ cell cancer	0.000254	0.000394	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—germ cell cancer	0.000254	0.00197	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—germ cell cancer	0.000252	0.00196	CbGpPWpGaD
Everolimus—Anorexia—Methotrexate—germ cell cancer	0.00025	0.000388	CcSEcCtD
Everolimus—Hypotension—Methotrexate—germ cell cancer	0.000245	0.00038	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—germ cell cancer	0.000245	0.00191	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—germ cell cancer	0.000241	0.00188	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.000239	0.000371	CcSEcCtD
Everolimus—Insomnia—Methotrexate—germ cell cancer	0.000238	0.000368	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—germ cell cancer	0.000236	0.000366	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—germ cell cancer	0.000234	0.000363	CcSEcCtD
Everolimus—Somnolence—Methotrexate—germ cell cancer	0.000234	0.000362	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—HRAS—germ cell cancer	0.000232	0.0018	CbGpPWpGaD
Everolimus—Dyspepsia—Methotrexate—germ cell cancer	0.000231	0.000358	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—HRAS—germ cell cancer	0.00023	0.00179	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF4—germ cell cancer	0.000229	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—germ cell cancer	0.000229	0.00178	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	0.000229	0.00178	CbGpPWpGaD
Everolimus—Decreased appetite—Methotrexate—germ cell cancer	0.000228	0.000354	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—HRAS—germ cell cancer	0.000228	0.00177	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—germ cell cancer	0.000227	0.00177	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.000227	0.000352	CcSEcCtD
Everolimus—Fatigue—Methotrexate—germ cell cancer	0.000226	0.000351	CcSEcCtD
Everolimus—Pain—Methotrexate—germ cell cancer	0.000225	0.000348	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	0.000224	0.00174	CbGpPWpGaD
Everolimus—Feeling abnormal—Methotrexate—germ cell cancer	0.000216	0.000336	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—germ cell cancer	0.000215	0.000333	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—HRAS—germ cell cancer	0.000214	0.00166	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	0.000214	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—germ cell cancer	0.000214	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—germ cell cancer	0.000212	0.00165	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—germ cell cancer	0.00021	0.00163	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGFR3—germ cell cancer	0.000209	0.00163	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—germ cell cancer	0.000209	0.00162	CbGpPWpGaD
Everolimus—Abdominal pain—Methotrexate—germ cell cancer	0.000208	0.000322	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—germ cell cancer	0.000208	0.000322	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—H2AFZ—germ cell cancer	0.000205	0.00159	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR3—germ cell cancer	0.000201	0.00156	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR3—germ cell cancer	0.0002	0.00156	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF4—germ cell cancer	0.0002	0.00155	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—germ cell cancer	0.000198	0.00154	CbGpPWpGaD
Everolimus—Hypersensitivity—Methotrexate—germ cell cancer	0.000194	0.0003	CcSEcCtD
Everolimus—MTOR—Innate Immune System—KIT—germ cell cancer	0.000192	0.00149	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	0.000189	0.00147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KITLG—germ cell cancer	0.000189	0.00147	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—germ cell cancer	0.000188	0.000292	CcSEcCtD
Everolimus—Pruritus—Methotrexate—germ cell cancer	0.000186	0.000288	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KIT—germ cell cancer	0.000184	0.00143	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF4—germ cell cancer	0.000184	0.00143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AVP—germ cell cancer	0.000184	0.00143	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KIT—germ cell cancer	0.000184	0.00143	CbGpPWpGaD
Everolimus—Diarrhoea—Methotrexate—germ cell cancer	0.00018	0.000279	CcSEcCtD
Everolimus—Dizziness—Methotrexate—germ cell cancer	0.000174	0.000269	CcSEcCtD
Everolimus—Vomiting—Methotrexate—germ cell cancer	0.000167	0.000259	CcSEcCtD
Everolimus—Rash—Methotrexate—germ cell cancer	0.000166	0.000257	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—germ cell cancer	0.000165	0.000256	CcSEcCtD
Everolimus—Headache—Methotrexate—germ cell cancer	0.000165	0.000255	CcSEcCtD
Everolimus—MTOR—Disease—H2AFZ—germ cell cancer	0.000165	0.00128	CbGpPWpGaD
Everolimus—MTOR—Immune System—KITLG—germ cell cancer	0.000164	0.00127	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—germ cell cancer	0.000162	0.00126	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—germ cell cancer	0.000156	0.000242	CcSEcCtD
Everolimus—MTOR—Disease—KITLG—germ cell cancer	0.000151	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—OXT—germ cell cancer	0.000151	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—germ cell cancer	0.000146	0.00113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR3—germ cell cancer	0.00014	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF4—germ cell cancer	0.000129	0.001	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—germ cell cancer	0.000129	0.001	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR3—germ cell cancer	0.000122	0.000947	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—H2AFZ—germ cell cancer	0.000115	0.000896	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR3—germ cell cancer	0.000113	0.000875	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—germ cell cancer	0.000112	0.00087	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KITLG—germ cell cancer	0.000106	0.000824	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AVP—germ cell cancer	0.000104	0.000806	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—germ cell cancer	0.000103	0.000803	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—germ cell cancer	0.000101	0.000786	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—germ cell cancer	8.3e-05	0.000645	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—germ cell cancer	7.97e-05	0.00062	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—germ cell cancer	7.94e-05	0.000617	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—germ cell cancer	7.88e-05	0.000613	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—germ cell cancer	7.23e-05	0.000562	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A3—germ cell cancer	7.13e-05	0.000554	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—germ cell cancer	7.08e-05	0.00055	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC22A3—germ cell cancer	7.02e-05	0.000546	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—germ cell cancer	5.81e-05	0.000452	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CRABP1—germ cell cancer	5.72e-05	0.000445	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—germ cell cancer	5.68e-05	0.000442	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—germ cell cancer	5.56e-05	0.000432	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—germ cell cancer	4.84e-05	0.000376	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—germ cell cancer	4.46e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—germ cell cancer	3.98e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—germ cell cancer	3.27e-05	0.000254	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—germ cell cancer	3.13e-05	0.000243	CbGpPWpGaD
